Aptorum Group Limited (APM) Financial Analysis & Valuation | Quarter Chart
Aptorum Group Limited (APM)
APMPrice: $0.84
Fair Value: 🔒
🔒score
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 ... more
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and comme... more
Description
Shares
| Market Cap | $5.32M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Chung Yuen Huen |
| IPO Date | 2018-12-18 | CAGR | — |
| Employees | 1 | Website | www.aptorumgroup.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
APM chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.86M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.27 |
| P/CF Ratio | 68.67 | P/FCF Ratio | 59.28 |
| EPS | $-0.19 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.06% | ROA | -0.07% |
| ROCE | -0.13% | Current Ratio | 0.78 |
| Quick Ratio | 0.78 | Cash Ratio | 0.75 |
| Debt/Equity | 0.15 | Interest Coverage | -24.73 |
| Altman Z Score | -5.96 | Piotroski Score | 1 |